Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CYP26A1 | O43174 | 3/20 | 0.46 |
| ▸ | FABP4 | P15090 | 1/20 | 0.46 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.46 |
| ▸ | CASP6 | P55212 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1421898 | 0.88 | HPGD (0.65) | GAAHPGDALDH1A1LMNAPOLB | |
| SCHEMBL12255153 | 0.82 | LMNA (0.58) | HPGDALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL5310632 | 0.81 | CA12 (0.48) | HPGDLMNAHTTSMN1; SMN2 | |
| SCHEMBL7761720 | 0.81 | HPGD (0.58) | HPGDALDH1A1LMNAHTTSMN1; SMN2 | |
| SCHEMBL5346088 | 0.81 | HPGD (0.46) | GAAHPGDALDH1A1LMNAHTT | |
| SCHEMBL9489980 | 0.80 | HPGD (0.57) | GAAHPGDALDH1A1LMNAHTT | |
| SCHEMBL1422207 | 0.80 | ALDH1A1 (0.63) | GAAHPGDALDH1A1LMNAPOLB | |
| SCHEMBL8866950 | 0.79 | HPGD (0.51) | HPGDLMNAHTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL11153249 | 0.78 | HPGD (0.59) | HPGDLMNAPOLBHTTSMN1; SMN2 | |
| SCHEMBL7761718 | 0.78 | HPGD (0.55) | HPGDALDH1A1LMNAHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2007-01-11 | — | — | US | disclosed |
| CN-1608061-A | Therapeutic isoquinoline compounds | ASTRAZENECA AB (SE) | 2005-04-20 | — | — | CN | disclosed |
| EP-1451172-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | AstraZeneca AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003037887-A1 | THERAPEUTIC ISOQUINOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010526-A1 | Therapeutic isoquinoline compounds | HTR1B, HTR1D, HTR1A | GAA 639/4885HPGD 918/4885ALDH1A1 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.